Articles from Baxter International Inc.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time.

Baxter International Inc. (NYSEBAX), a global leader in injectables, anesthesia and drug compounding, today announced five new injectable pharmaceutical product launches in the U.S., joining the previous five launches announced in April of this year and marking a total of 10 U.S. injectable product launches in 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the third quarter of 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:15 p.m. Pacific Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a global medtech leader, today shared updates regarding the impact of Hurricane Helene, which brought unprecedented rain and extensive flooding to Western North Carolina, on the operations of its North Cove facility in Marion, N.C.

Baxter International Inc. (NYSEBAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort and additional patient-centered features driven by clinician and patient input.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter’s Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:30 p.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, and funds managed by global investment firm Carlyle NASDAQ:CGNASDAQCG)

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the second quarter of 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I898552708 to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on Oct. 1, 2024, to stockholders of record as of Aug. 30, 2024. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today published its 2023 Corporate Responsibility Report. The annual report showcases Baxter’s dedication to making a meaningful difference in global healthcare and reporting with transparency on the environmental, social and governance topics most important to its stakeholders.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:40 a.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD). The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 2, 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.

Baxter International Inc. (NYSEBAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated. Clinolipid has been available in the U.S. for adults since 2019 and is now available for use in all ages.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 3:00 p.m. Pacific Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Wednesday, August 14, 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 1, 2024, to stockholders of record as of May 31, 2024. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the first quarter of 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – enables clinicians to utilize a single, integrated system across a variety of patient care settings. Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting. Online access to the 2024 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2024 Annual Meeting in person. The virtual format provides a convenient and cost-effective experience to all stockholders and employees regardless of location.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot. Launched in conjunction with Northwestern Medicine, a premier integrated academic health system in Chicago, more than six tons (or 12,000 pounds) of polyvinyl chloride (PVC) IV bag waste — enough to cross the city of Chicago if bags were laid end-to-end — has been successfully diverted from landfill to be recycled for a useful second life. This program is the first of its kind to launch in the U.S.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, today published its first report aligned with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations, which were recently incorporated into the International Sustainability Standards Board Standards. The TCFD framework is designed to help improve climate-related disclosure that is relevant to Baxter’s investors and other key stakeholders in the areas of governance, strategy, risk management, and metrics and targets. The publication of the TCFD report comes as Baxter is named to the Dow Jones Sustainability Index (DJSI) North America for 2023, recognizing the company’s leading sustainability efforts. Baxter has proudly been included in DJSI North America each year since it launched in 2005.

The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSEBAX), and UNICEF, today announced a partnership to improve access to safe drinking water and sanitation in five water-challenged regions in Egypt. Supported by a $2.5 million grant from the Foundation, this three-year initiative aims to implement climate-smart water, sanitation and hygiene (WASH) programming for thousands of people in Upper Egypt’s governorates of Aswan, Assiut, Quena, Minya and Luxor through community engagement, education and rehabilitation of primary health units.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on January 2, 2024, to shareholders of record as of December 1, 2023. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global innovator in kidney care and vital organ support, announced today new data indicating Baxter’s Sharesource remote patient management (RPM) digital platform, when used with an automated peritoneal dialysis (PD) system, is associated with a 77% reduction in risk of PD technique failure. Technique failure can be due to several factors and results in PD patients being switched to in-center dialysis. Additional key data show HDx therapy enabled by Theranova dialyzer provides expanded hemodialysis therapy, which can help reduce annual water consumption by 27% and annual electricity usage by 17%, and associated costs, in comparison with online HDF (hemodiafiltration).

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the third quarter of 2023.

Baxter International Inc. (NYSEBAX), a leader in patient monitoring, physical assessment and vision screening products, announced the launch of digital image capture capability for eye exams using its existing Welch Allyn PanOptic Plus Ophthalmoscope. The iExaminer Pro System adds a key technology to routine eye exams, designed to help advance healthcare professionals’ ability to examine and diagnose the eye health of patients.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, Brian Stevens, who has served as the company’s interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its third-quarter 2023 financial results on Thursday, November 2, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023. José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer is scheduled to present at 8:45 a.m. EST.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced it has appointed Stephen (Steve) H. Rusckowski, former chairman, president and chief executive officer of Quest Diagnostics, Inc., to its board of directors. Effective today, Mr. Rusckowski serves on Baxter’s Compensation and Human Capital, and Quality, Compliance and Technology Committees. In addition, the company has announced that Michael (Mike) Mahoney will be resigning from the board effective Sept. 13, 2023, following nearly eight years of service.

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the second quarter of 2023.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions.

Baxter International Inc. (NYSEBAX), a global leader in advancing surgical innovation, today announced the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.1

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on October 2, 2023, to shareholders of record as of September 1, 2023. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced it has appointed William A. Ampofo II, chair, Supply Chain Operations Council and vice president, Parts & Distribution Services and Supply Chain, Boeing Global Services, to its board of directors. Mr. Ampofo will serve on Baxter’s Quality, Compliance & Technology Committee. His appointment is effective today and brings the total number of directors serving the company to 11.

Baxter International Inc. (NYSEBAX), an innovator in connected beds for med-surg and the intensive care unit (ICU), announced today the U.S. launch of its new Hillrom Progressa+ bed for the ICU. Progressa+ offers new technology and features that help make it easier for nurses to care for patients, while supporting patient recovery.

Baxter International Inc. (NYSEBAX), a global medtech leader, today published its 2022 Corporate Responsibility Report. The annual report, which features performance updates on the company’s 2030 Corporate Responsibility Commitment and Goals, demonstrates Baxter’s steadfast commitment to operating as a responsible corporate citizen and to providing transparent information on the environmental, social and governance topics most important to its stakeholders.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its second-quarter 2023 financial results on Thursday, July 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/XvgzXupv to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023. José (Joe) Almeida, Baxter’s chairman, president and chief executive officer, is scheduled to present at 10:00 a.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Jay Saccaro. Mr. Saccaro will leave Baxter at the end of May after 21 cumulative years with the company, including the past eight as CFO, to join a company in the healthcare industry.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses. Until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by July 2024 or earlier, Mr. Toth will serve as executive vice president and group president, Kidney Care, and report to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective June 1, 2023.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 3, 2023, to shareholders of record as of June 2, 2023. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the first quarter of 2023.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/WhpPxesO to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a global leader in sterile medication production and delivery, today announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers. Please see Indications, Important Risk Information and link to full Prescribing Information below.

Baxter International Inc. (NYSEBAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023. These innovations include the launch of the new Baxter Patient Warming system, the unveiling of the Helux Pro Connected Surgical Light, and the launch of Floseal + Recothrom flowable hemostat, all of which are on display in Baxter’s AORN booth #2027.

Baxter International Inc. (NYSEBAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2023 Annual Meeting) in a virtual format on Tuesday, May 2, 2023 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the meeting. Online access to the meeting will begin at 8:30 a.m., Central Time. Stockholders will not be able to attend the meeting in person. If you plan to attend the virtual meeting, please check https://investor.baxter.com for updates prior to the meeting date.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on April 3, 2023, to shareholders of record as of February 24, 2023. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023.

Miromatrix Medical Inc. (NASDAQMIRO) and Baxter International Inc. NYSE:BAXNYSEBAX)

Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2022 financial results on Thursday, February 9, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information.

Baxter International Inc. (NYSEBAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders. These changes include the plan to spin off the company’s Renal Care and Acute Therapies global business units (GBUs) into an independent, publicly traded company; a simplified commercial and manufacturing footprint to enhance underlying business performance; and further portfolio actions to improve Baxter’s capital structure, including a review of strategic alternatives for the BioPharma Solutions (BPS) business.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced it was again named to the Dow Jones Sustainability Indices (DJSI), including both DJSI World and DJSI North America. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively.

Baxter International Inc. (NYSEBAX), a global leader in nutrition therapy, announces the launch of the ExactaMix Pro Automated Compounder, which is expected to be available to customers in the United States in early 2023. ExactaMix Pro will be on display at Baxter’s booth #937 at the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting taking place Dec. 4 – Dec. 8, 2022, in Las Vegas.

Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.

Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on January 3, 2023, to shareholders of record as of December 2, 2022. The indicated annual dividend rate is $1.16 per share of common stock.

Baxter International Inc. (NYSEBAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis (HDx) care at Kidney Week 2022, Nov. 3-6, Orlando, Florida. Key data highlighted include: